The role of age-related androgen deficiency in the pathogenesis of prostate adenoma

Written by Tyuzikov I.A., Bratchikov O.I., Michajlov D.V., Schumakova E.A., Churaev S.A.

  UDK: 616.65-006.55-053.87:612.433,451 | Pages: 14–18 | Full text PDF | Open PDF 


A literature review on the role of age-related androgen deficiency in the pathogenesis of prostatic adenoma (benign prostate hyperplasia) (PA). Testosterone is the most important sex hormone that provides almost all of the prostate and bladder functions, and age-related decline synthesis in men coincides with the advent of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia. These and other well-known pathophysiological mechanisms of participation of the age-related androgen deficiency in the pathogenesis of PA are presented in this review. Based on an analysis of published data, we can conclude that prostate hyperplasia is a combined therapeutic problem, and pathogenic decision may be associated exclusively with the interdisciplinary approach, and among the most important levers we should consider the early detection and correction of age-related androgen deficiency in all men with LUTS/PA.

Links to authors:

I.A. Tyuzikov1, O.I. Bratchikov2, D.V. Michajlov2, E.A. Schumakova2, S.A. Churaev3
1 Clinic of Professor Kalinchenko (4/2 Butyrskaya St. Moscow 127015 Russian Federation),
2 Kursk State Medical University (3 Karl Marks St. Kursk 305041 Russian Federation),
3 Kursk City Hospital No. 1 named after N.S. Korotkov (76 Semenovskaya St. Kursk 305004 Russian Federation)

1. Prostate gland diseases / edited by Yu.G. Alyaev. М.: GEOTARMedia, 2009. 240 p.
2. Kalinichenko S.Yu., Tyuzikov I.A. Prostate gland disease and the metabolic syndrome: a new pathogenetic concept (literature review) // Medical Alphabet. Hospital. 2011. No. 4. P. 38–43.
3. Kalinichenko S.Yu., Tyuzikov I.A., Vorslov O.L., Tishova Yu.A. Asymptomatic benign prostatic hyperplasia: to treat or not to treat? // Effective Pharmatherapy. Urology. 2012. No. 4. P. 50–53.
4. Kalinichenko S.Yu., Tyuzikov I.A., Grekov E.A. [et al.]. Metabolic syndrome and benign prostatic hyperplasia: the unity of the pathophysiological mechanisms and new perspectives pathogenetic therapy // Consilium Medicum. 2012. No. 7. P. 19–24.
5. Kalinichenko S.Yu., Tyuzikov I.A., Grekov E.A. [et al.]. Combination therapy with androgens and inhibitors of 5α-reductase inhibitors in the treatment of BPH patients with age-related hypogonadism: appropriateness, effectiveness and safety // Consilium Medicum. 2012. No. 7. P. 10–18.
6. Kirpatovskiy V.I., Mudraya I.S., Grekov E.A. Effect of experimentally induced metabolic syndrome on the functional state of the bladder in rats // Experimental and Clinical Urology. 2013. No. 1. P. 8–13.
7. Kirpatovskiy V.I., Mudraya I.S., Revenko S.V. [et al.]. Evaluation of intramural blood flow and regulation of neurogenic intact and hypertrophied rat bladder using harmonic analysis bioimpedance // Bulletin of Experimental Biology and Medicine. 2012. Vol. 153, No. 4. P. 422–427.
8. Tyuzikov I.A. Clinical and experimental parallels in the pathogenesis of prostate gland diseases // Modern problems of science and education. 2012. No. 1. URL: www.science-education. ru/101-5476 (date of access: 08.02.2012).
9. Tyuzikov I.A., Kalinichenko S. Yu., Vorslov L.O., Tishova Yu.A. Androgen deficiency in the clinical case of modern surgical patient // Andrology and Genital Surgery. 2013. No. 3. P. 48–57.
10. Tyuzikov I.A., Martov A.G., Grekov E.A. The relationship of components of the metabolic syndrome, and hormonal disorders in the pathogenesis of prostate diseases (literature review) // Experimental and Clinical Urology. 2012. No. 3. P. 39–46.
11. Tyuzikov I.A., Martov A.G., Kalinichenko S.Yu. New system mechanisms of the pathogenesis of lower urinary tract symptoms (LUTS) in men (literature review) // Bulletin of Siberian Medicine. 2012. No. 2. С. 93–100.
12. Tyuzikov I.A., Fomin A.M., Kalinichenko S.Yu., Martov A.G. System mechanisms of the pathogenesis of diseases of the prostate gland (literature review) // Andrology and Genital Surgery. 2012. No. 2. P. 4–12.
13. Urology. National Guide / edited by N.A. Lopatkin. М.: GEOTAR- Media, 2009. 1024 p.
14. Almasri A.M., Ratz P.H., Bhatia H. [et al.]. Rhythmic contraction generates adjustable passive stiffness in rabbit detrusor // J. Appl. Physiol. 2010. Vol. 108. P. 544–553.
15. Ansari M.A., Begum D., Islam F. Serum sex steroids, gonadotrophins and sex hormonebinding globulin in prostatic hyperplasia // Ann. Saudi. Med. 2008. Vol. 28. P. 174–178.
16. Azadzoi K.M., Babayan R.K., Kozlowski R., Siroky M.B. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit // J. Urol. 2003. Vol. 170, No. 2. Pt. 1, P. 659–663.
17. Azadzoi K.M., Tarcan T., Siroky M.B. Atherosclerosis-induced chronic ischemia causes bladder fibrosis and non-compliance in the rabbits // J. Urol. 1999. Vol. 161. P. 1626–1635.
18. Chawnshang C. Androgens and androgen receptor: mechanisms, functions, and clinical applications. USA: Kluwer Academic Publishers, 2002. 503 p.
19. Corona G., Monami M., Rastrelli G. [et al.]. Testosterone and metabolic syndrome: a meta-analysis study // J. Sex. Med. 2011. Vol. 8, No. 1. P. 272–283.
20. Corona G., Vignozzi L., Rastrelli G. [et al.]. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions // Int. J. Endocrinol. 2014. Article ID 329456. 14 p.
21. Demir O., Akgul K., Akar Z. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome // Aging Male. 2009. Vol. 12. P. 29–34.
22. Espinosa G., Esposito R., Kazzazi A., Djavan B. Vitamin D and benign prostatic hyperplasia – a review // Can. J. Urol. 2013. Vol. 20, No. 4. P. 6820–6825.
23. Gacci M., Corona G., Vignozzi L., Salvi M. [et al.]. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis // BJU Int. 2015. Vol. 115, No. 1. P. 24–31.
24. Godoy A., Montecinos V.P., Gray D.R. [et al.]. Androgen deprivation induces rapid involution and recovery of human prostate vasculature // Am. J. Physiol. Endocrinol. Metab. 2011. Vol. 300, No. 2. P. 263–275.
25. Gorbachinsky I., Akpinar H., Assimos D.G. Metabolic syndrome and urological diseases // Rev. Urol. 2010. Vol. 12, No. 4. P. 157–180.
26. Guideline on management of male low urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO) / Oelke M., Bachmann A., Descazeaud A. [et al.]. EAU, 2012. 74 p.
27. Gupta A., Gupta S., Pavuk M., Roehrborn C.G. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans // Urology. 2006. Vol. 68. P. 1198–1205.
28. Jacobsen S.J., Girman C.J, Guess H.A. [et al.]. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men // J. Urol. 1996. Vol. 155. P. 595–600.
29. Khan Z.A., Chakrabarti S. Endothelins in chronic diabetic complications // Can. J. Physiol. Pharmacol. 2003. Vol. 81. P. 622–634.
30. Kozlowski R., Kershen R.T., Siroky M.B. Chronic ischemia alters prostate structure and reactivity in rabbits // J. Urol. 2001. Vol. 165. P. 1019–1026.
31. Kupelian V., McVary K.T., Kaplan S.A. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey // J. Urol. 2009. Vol. 182. P. 616–624.
32. Lorenzetti F., Pintarelli V.L., Seraphim D.C., Dambros M. Low testosterone levels induce apoptosis via active 3-caspase dependent signaling in the bladder wall of male rats // Aging Male. 2012. Vol. 15, No. 4. P. 216–219.
33. Marberger M., Harkaway R., de la Rossete J. Optimizing the medical management of benign prostatic hyperplasia // Eur. Urol. 2004. Vol. 45, No. 4. P. 411–419.
34. McVary K.T., Rademaker A., Lloyd G.L., Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia // J. Urol. 2005. Vol. 174, No. 4. P. 1327–1333.
35. McСloskey K.D. Interstitial cells of Cajal in the urinary tract // Handb. Exp. Pharmacol. 2011. Vol. 202. P. 233–254.
36. Navarro-Dorado J., Orensanz L.M., Recio P., Bustamante S. [et al.]. Mechanisms involved in testosterone-induced vasodilatation in pig prostatic small arteries // Life Sci. 2008. Vol. 83, No. 15–16. P. 569–573.
37. Roberts R.O., Jacobson D.J., Rhodes T. Serum sex hormones and measures of benign prostatic hyperplasia // Prostate. 2004. Vol. 61. P. 124–131.
38. Shidaifat F., Lin Y.C. Testosterone effect on the expression of genes that mediate testosterone metabolism and genes that mediate the effect of those metabolites on the prostate // Life Sci. 2012. Vol. 91, No. 5–6. P. 194–198.
39. Sun Y., Wang B.E., Leong K.G. [et al.]. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy // Cancer Res. 2012. Vol. 72, No. 2. P. 527–536.
40. Uckert S., Kuczyk M.A. Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract // Handb. Exp. Pharmacol. 2011. Vol. 202. P. 527–542.
41. Vignozzi L., Cellai I., Santi R., Lombardelli L. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells // J. Endocrinol. 2012. Vol. 214, No. 1. P. 31–43.
42. Vignozzi L., Morelli A., Sarchielli E. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit // J. Endocrinol. 2012. Vol. 212, No. 1. P. 71–84.
43. Vignozzi L., Rastrelli G., Corona G., Gacci M. et al. Benign prostatic hyperplasia: a new metabolic disease? // J. Endocrinol. Invest. 2014. Vol. 37, No. 4. P. 313–322.
44. Yalçınkaya S., Eren E., Eroglu M. [et al.]. Deficiency of vitamin D and elevated aldosterone in prostate hyperplasia // Adv. Clin. Exp. Med. 2014. Vol. 23, No. 3. P. 441–446.
45. Yu S., Yeh C.R., Niu Y. [et al.]. Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts // Prostate. 2012. Vol. 72, No. 4. P. 437–449.
46. Zhang Y., Chen J., Hu L., Chen Z. Androgen deprivation induces bladder histological abnormalities and dysfunction via TGF-β in orchiectomized mature rats // Tohoku J. Exp. Med. 2012. Vol. 226, No. 2. P. 121–128.
47. Zhang X., Zang N., Wei Y., Yin J. Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling // Am. J. Physiol. Endocrinol. Metab. 2012. Vol. 302, No. 2. P. 243–253.


Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.